Risks and benefits of testosterone therapy in older men. (Q38099508)

28 August 2017

title

Risks and benefits of testosterone therapy in older men. (English)

1 reference

28 August 2017

1 reference

1 reference

Shalender Bhasin

1 reference

28 August 2017

Grace Huang

1 reference

28 August 2017

Shehzad Basaria

1 reference

28 August 2017

Thomas G Travison

1 reference

28 August 2017

Matthew Spitzer

1 reference

28 August 2017

publication date

16 April 2013

1 reference

Nature Reviews Endocrinology

28 August 2017

published in

1 reference

28 August 2017

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

414-424

1 reference

A UK epidemic of testosterone prescribing, 2001-2010

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Clinical review: Why is androgen replacement in males controversial?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Prevalence of symptomatic androgen deficiency in men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

The epidemiology of plasma testosterone levels in middle-aged men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone and estradiol among older men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Identification of late-onset hypogonadism in middle-aged and elderly men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Reference ranges and determinants of testosterone, dihydrotestosterone, and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Longitudinal Relation between Endogenous Testosterone and Cardiovascular Disease Risk Factors in Middle-aged Men: A 13-Year Follow-up of Former Multiple Risk Factor Intervention Trial Participants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Endogenous testosterone levels, physical performance, and fall risk in older men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

The relationship between libido and testosterone levels in aging men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Deterioration of trabecular architecture in hypogonadal men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Effect of testosterone replacement on trabecular architecture in hypogonadal men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Sex steroid hormones in older men: longitudinal associations with 4.5-year change in hip bone mineral density--the osteoporotic fractures in men study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Association of Testosterone and Estradiol Deficiency with Osteoporosis and Rapid Bone Loss in Older Men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Endogenous Sex Steroids and Bone Mineral Density in Older Women and Men: The Rancho Bernardo Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Low testosterone levels and the risk of anemia in older men and women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Association between sex steroid hormones and hematocrit in a nationally representative sample of men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Sex hormones and frailty in older men: the osteoporotic fractures in men (MrOS) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Free testosterone levels are associated with mobility limitation and physical performance in community-dwelling men: the Framingham Offspring Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Association of Hypogonadism and Estradiol Levels with Bone Mineral Density in Elderly Men from the Framingham Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Sex hormone-binding globulin, but not testosterone, is associated prospectively and independently with incident metabolic syndrome in men: the framingham heart study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Androgens and coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Plasma testosterone and dehydroepiandrosterone sulfate in male and female patients with dysthymic disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Low testosterone levels in elderly men with dysthymic disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Sex steroid level, androgen receptor polymorphism, and depressive symptoms in healthy elderly men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Androgen-behavior correlations in hypogonadal men and eugonadal men. I. Mood and response to auditory sexual stimuli

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Changes in erectile responsiveness during androgen replacement therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

The endocrine effects of visual erotic stimuli in normal men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Androgen and sleep-related erections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Effects of testosterone on sexual function in men: results of a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Sexual dysfunction in men and women with endocrine disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Secondary hypogonadism in older men: its relation to impotence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Prevalence of androgen deficiency in men with erectile dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Low testosterone levels and decline in physical performance and muscle strength in older men: findings from two prospective cohort studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone, dehydroepiandrosterone, and physical performance in older men: results from the Massachusetts Male Aging Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone administration to older men improves muscle function: molecular and physiological mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

DHEA in elderly women and DHEA or testosterone in elderly men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone dose-response relationships in healthy young men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone inhibits transforming growth factor-β signaling during myogenic differentiation and proliferation of mouse satellite cells: potential role of follistatin in mediating testosterone action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Regulation of myogenic differentiation by androgens: cross talk between androgen receptor/ beta-catenin and follistatin/transforming growth factor-beta signaling pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Differential anabolic effects of testosterone and amino acid feeding in older men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Adverse events associated with testosterone administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Effects of Transdermal Testosterone on Bone and Muscle in Older Men with Low Bioavailable Testosterone Levels, Low Bone Mass, and Physical Frailty

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Frailty in older adults: evidence for a phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Effect of oral testosterone undecanoate on visuospatial cognition, mood and quality of life in elderly men with low-normal gonadal status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Intramuscular testosterone treatment in elderly men: evidence of memory decline and altered brain function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone treatment enhances regional brain perfusion in hypogonadal men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Sex hormone-binding globulin as an independent predictor of incident type 2 diabetes mellitus in men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Type 2 diabetes mellitus and testosterone: a meta-analysis study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Effect of testosterone administration on liver fat in older men with mobility limitation: results from a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Control of human sebocyte proliferation in vitro by testosterone and 5-alpha-dihydrotestosterone is dependent on the localization of the sebaceous glands.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Immunocytochemical Localization of Androgen Receptors in Human Skin Using Monoclonal Antibodies Against the Androgen Receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Differences in the Apparent Metabolic Clearance Rate of Testosterone in Young and Older Men with Gonadotropin Suppression Receiving Graded Doses of Testosterone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Effects of graded doses of testosterone on erythropoiesis in healthy young and older men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Hematocrit and the risk of cardiovascular disease--the Framingham study: a 34-year follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Increased hematocrit before blood pressure in men who develop hypertension over 20 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Hematocrit, viscosity and coronary blood flow

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

The effect of hemodilution on regional myocardial function in the presence of coronary stenosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Does sticky blood predict a sticky end? Associations of blood viscosity, haematocrit and fibrinogen with mortality in the West of Scotland

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone and atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Androgens and cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Endogenous sex hormones and cardiovascular disease in men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Relation of total and free testosterone and sex hormone-binding globulin with cardiovascular risk factors in men aged 24–45 years. The Cardiovascular Risk in Young Finns Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Low plasma testosterone and elevated carotid intima-media thickness: importance of low-grade inflammation in elderly men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Usefulness of sex steroid hormone levels in predicting coronary artery disease in men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Selective inhibition of L-type Ca2+ channels in A7r5 cells by physiological levels of testosterone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone and growth hormone improve body composition and muscle performance in older men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Testosterone treatment and mortality in men with low testosterone levels.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Obstructive sleep apnea syndrome induced by testosterone administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea: a randomized placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Depression of hypercapnic ventilatory drive by testosterone in the sleeping infant primate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

The short-term effects of high-dose testosterone on sleep, breathing, and function in older men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Obstructive sleep apnoea, cigarette smoking and serum testosterone levels in a male sleep clinic cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.73

Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial

31 March 2020

1 reference

12 December 2020

Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis

1 reference

12 December 2020

Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging

1 reference

12 December 2020

Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism

1 reference

12 December 2020

Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate

1 reference

12 December 2020

Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men

1 reference

12 December 2020

Testosterone replacement increases fat-free mass and muscle size in hypogonadal men.

1 reference

12 December 2020

Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity

1 reference

12 December 2020

Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials

1 reference

12 December 2020

Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men

1 reference

12 December 2020

Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study

1 reference

12 December 2020

A systematic review of augmentation strategies for patients with major depressive disorder.

1 reference

12 December 2020

Effects of testosterone supplementation in the aging male

1 reference

12 December 2020

Testosterone supplementation for erectile dysfunction: results of a meta-analysis

1 reference

12 December 2020

Short-term oxandrolone administration stimulates net muscle protein synthesis in young men.

1 reference

12 December 2020

Testosterone and Cardiovascular Risk in Men: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials

1 reference

12 December 2020

Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.

1 reference

12 December 2020

Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men--a clinical research center study

1 reference

12 December 2020

Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen

1 reference

12 December 2020

Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study

1 reference

12 December 2020

Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age

1 reference

12 December 2020

Effects of testosterone replacement in hypogonadal men.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2013.73

1 reference

28 August 2017

1 reference